ReviewCureus2025
The Role of Artificial Intelligence in the Prediction, Diagnosis, and Management of Cardiovascular Diseases: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond Traditional Risk Scores: Artificial Intelligence in Coronary Plaque Characterization and Personalized Atherosclerosis Management.Journal of cardiovascular development and disease · 2026Review
- [Artificial intelligence and disinformation in health: The need for re-education from primary care].Atencion primaria · 2026Review
- Longitudinal Myocardial Deformation as an Emerging Biomarker for Post-Traumatic Cardiac Dysfunction.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading global cause of mortality, and a high prevalence of cardiac conditions, including premature deaths, have increased from decades until today. However, early detection and management of these conditions are challenging, given their complexity, the scale of affected populations, the dynamic nature of the disease process, and the treatment approach. The transformative potential is being brought by Artificial Intelligence (AI), specifically machine learning (ML) and deep learning technologies, to analyze massive datasets, improve diagnostic accuracy, and optimize treatment strategy. The recent advancements in such AI-based frameworks as the personalization of decision-making support systems for customized medicine automated image assessments drastically increase the precision and efficiency of healthcare professionals. However, implementing AI is widely clogged with obstacles, including regulatory, privacy, and validation across populations. Additionally, despite the desire to incorporate AI into clinical routines, there is no shortage of concern about interoperability and clinician acceptance of the system. Despite these challenges, further research and development are essential for overcoming these hurdles. This review explores the use of AI in cardiovascular care, its limitations for current use, and future integration toward better patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.